User menu

An epigenetic approach to the treatment of advanced MDS; the experience with the DNA demethylating agent 5-aza-2 '-deoxycytidine (decitabine) in 177 patients

Bibliographic reference Wijermans, PW ; Lubbert, M ; Verhoef, G. ; Klimek, V ; Bosly, André. An epigenetic approach to the treatment of advanced MDS; the experience with the DNA demethylating agent 5-aza-2 '-deoxycytidine (decitabine) in 177 patients. In: Annals of Hematology, Vol. 84, p. 9-17 (2005)
Permanent URL
  1. Aoki E, Uchida T, Ohashi H, Murase T, Ichikawa A, Yamao K, Hotta T, Kinoshita T, Saito H, Murate T (2000) Methylation status of the p15ink4b gene in hematopoietic progenitors and peripheral blood cells in myelodysplastic syndrome. Leukemia 14:586–593
  2. Bennet JM, Catovskty D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, Sultan C (1982) Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 74:395–408
  3. Cheson BD, Bennett JM, Kantarjian H, Pinto A, Schiffer CA, Nimer SD, Lowenberg B, Beran M, de Witte T, Stone RM, Mittelman M, Sanz GF, Wijermans PW, Gore S, Greenberg P (2000) Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood 96:3671–3674
  4. Cheson BD, Jaspern DM, Simon R, Friedman MA (1986) A critical appraisal of low dose cytosine arabinoside in patients with acute non lymphocytic leukaemia and myelodysplastic syndrome. J Clin Oncol 4:1857–1864
  5. Christman JK (2002) 5-azacytidine and 5-aza-2′-deoxycytidine as inhibitors of DNA methylation: mechanistic studies and their implications for cancer therapy. Oncogene 21:5483–5495
  6. Clark SJ, Melki J (2002) DNA methylation and gene silencing in cancer: which is the guilty party? Oncogene 21:5380–5387
  7. Daskalakis M, Nguyen TT, Nguyen C, Goldberg P, Ko G, Wijermaqns P, Jones PA, Lübbert M (2002) Demethylation of a hypermethylated P15/INK4B gene in patients with myelodysplastic syndrome by 5-aza-2′-deoxycytidine (decitabine) treatment. Blood 100:2957–2964
  8. Erratum (1998) Blood 91:1100
  9. Greenberg P, Cox C, Le Bau MM, Fenaux P, Morel P, Sanz G, Sanz M, Vallespi T, Hamblin T, Oscier D, Ohyashi K, Toyama K, Aul C, Mufti G, Bennett J (1997) International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 89:2079–2088
  10. Kaminskas E, Farrell A, Abraham S, Baird A, Hsieh LS, Lee SL, Leighton JK, Patel H, Rahman A, Sridhara R, Wang YC, Pazdur R, FDA (2005) Approval summary: azacitidine for treatment of myelodysplastic syndrome subtypes. Clin Cancer Res 11:3604–3608
  11. Kornblith AB, Herndon JE, Silverman LR, Demakos EP, Odchimar-Reissig R, Holland JF, Powell BL, DeCastro C, Ellerton J, Larson RA, Schiffer CA, Holland JC (2002) Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: a Cancer and Leukemia Group B Study. J Clin Oncol 15:2441–2452
  12. Kurzrock R, Albitar M, Cortes JE, Estey EH, Faderl SH, Garcia-Manero G, Thomas DA, Giles FJ, Ryback ME, Thibault A, De Porre P, Kantarjian HM (2004) Phase II study of R115777, a farnesyl transferase inhibitor, in myelodysplastic syndrome. J Clin Oncol 22:1287–1292
  13. Lübbert M, Wijermans P, Kunzman R, Verhoef G, Bosly A, Ravoet C, Andre M, Ferrant A (2001) Cytogenetic responses in high risk myelodysplastic syndrome following low dose treatment with the DNA methylation inhibitor 5-aza-2′-deoxycytidine. Br J Haematol 114:1–11
  14. Miller KB, Kim K, Morrison FS, Winter JN, Bennett JM, Neiman RS, Head DR, Cassileth PA, O'Connell MJ, Kyungmann K (1992) The evaluation of low dose cytarabine in the treatment of myelodysplastic syndrome: a phase III intergroup study. Ann Hematol 65:162–168
  15. Quesnel B, Guillerm G, Vereecque R, Wattel E, Preudhomme C, Bauters F, Vanrumbeke M, Fenaux P (1998) Methylation of the p15ink4b gene in myelodysplastic syndrome is frequent and acquired during disease progression. Blood 91:2985–2990
  16. Silverman LR, Demakos EP, Peterson BL, Kornblith AB, Holland JC, Odchimar-Reissig R, Stone RM, Nelson D, Powell BL, DeCastro CM, Ellerton J, Larson RA, Schiffer CA, Holland JM (2002) Randomized controlled trial of azacytidine in patients with the myelodysplastic syndrome: a study of the Cancer and Leukemia Group B. J Clin Oncol 20:2429–2440
  17. Wijermans PW, Krulder JWM, Huijgens PC, Neve P (1997) Continuous infusion of low dose 5-aza-2′-deoxycytidine in elderly patients with high risk myelodysplastic syndrome. Leukemia 11:1–5
  18. Wijermans P, Lübbert M, Verhoef G, Bosly A, Ravoet C, Andre M, Ferrant A (2002) Low dose 5-aza-2′-deoxycytidine, a DNA hypomethylating agent, for the treatment of high risk myelodysplastic syndrome: a multicenter phase II study in elderly patients. J Clin Oncol 18:956–962